MedTrace Logo

S0410 Tandem Stem Cell Transplantation in Treating Patients With Progressive or Recurrent Hodgkin's Lymphoma

NCT00233987 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 98

Last updated 2018-03-01

Study results available
· View outcomes & findings →

Summary

RATIONALE: Radiation therapy uses high-energy x-rays to kill cancer cells. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving chemotherapy with a peripheral stem cell transplant may allow more chemotherapy to be given so that more cancer cells are killed. Tandem (two) autologous stem cell transplants may be an effective treatment for Hodgkin's lymphoma.

PURPOSE: This phase II trial is studying how well tandem stem cell transplantation works in treating patients with progressive or recurrent Hodgkin's lymphoma.

Conditions

Interventions

DRUG

carmustine

150 mg/m\^2 IV over 2 hours 4, 5, and 6 days before transplant.

DRUG

cyclophosphamide

100 mg/kg IV 2 days before transplant.

DRUG

etoposide

60 mg/kg IV over 4 hours 4 days before transplant.

DRUG

melphalan

150 mg/m\^2 IV 1 day before transplant.

PROCEDURE

autologous-autologous tandem hematopoietic stem cell transplantation

2.0 x 10\^6 CD34+ cells, beginning at least 24 hours after melphalan infusion.

RADIATION

radiation therapy

150 centigray (cGy) total body irradiation given b.i.d on days 5-8 before transplant.

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • SWOG Cancer Research Network

    lead NETWORK

Principal Investigators

  • Eileen P. Smith, MD · City of Hope Comprehensive Cancer Center

  • Patrick J. Stiff, MD · Loyola University

  • Louis S. Constine, MD · James P. Wilmot Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
15 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-10-31
Primary Completion
2014-11-30
Completion
2017-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00233987 on ClinicalTrials.gov